OSCR

Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma.

Overview

Authors: Jesse A Coker1,2, Steven R Martinez2, Sang Hoon Han2,3, Anthony R Sloan4,5, Amit Kumar Gupta6,7, George Bukenya4, Paul Polzer2, James H Ramos4, Emma G Rico2, Annabella Rico2, A Abigail Lindsey2, Tanvi Navadgi4, Natalie Reitz4, Todd Romigh2, Jonathan Macdonald2, Dhiraj Sonawane2, Christopher M Goins1,2, Christopher G Hubert5,8, Nancy S Wang2, Feixiong Cheng1,5,6,7, Joseph Alvarado1,2, Samuel A Sprowls9,10, Justin D Lathia4,5,11, Shaun R Stauffer1,2
  1. Department of Molecular Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA
  2. Cleveland Clinic Center for Therapeutics Discovery (C3TD), Cleveland Clinic Research, Cleveland, Ohio, USA
  3. College of Pharmacy, Korea University, Sejong, Korea
  4. Department of Cardiovascular Medicine, Cleveland Clinic Research, Cleveland, Ohio, USA
  5. Case Comprehensive Cancer Center, Case Western Reserve University, Cleveland, Ohio, USA
  6. Cleveland Clinic Genome Center and
  7. Genomic Medicine Institute, Cleveland Clinic Research, Cleveland, Ohio, USA
  8. Department of Biochemistry, Case Western Reserve University, Cleveland, Ohio, USA
  9. PASS Division and
  10. Graudate School of Pharmaceutical Sciences, Duquesne University School of Pharmacy, Pittsburgh, Pennsylvania, USA
  11. Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic Research, Cleveland, Ohio, USA
Institutions: Cleveland Clinic (United States); Cleveland Clinic Lerner College of Medicine (United States); Case Western Reserve University (United States); Korea University (South Korea); Case Comprehensive Cancer Center (United States); Duquesne University (United States)
Journal: JCI insight, volume 11, issue 12, article e198298
Dates: received 22 July 2025; accepted 24 April 2026; published online 5 May 2026
Type: Research article · Language: English
License: CC BY
Identifiers: DOI 10.1172/jci.insight.198298 · PMID 42084925 · PMCID PMC13313556 · OpenAlex W4412817009
Open access: gold, a free copy (OpenAlex)
Categories: human (organism), mouse (organism), other condition (population)
Methods: Statistics
Keywords: Cell biology, Neuroscience, Oncology, Brain cancer, Structural biology, Therapeutics
MeSH: Antineoplastic Agents*, Brain Neoplasms*, Glioblastoma*, Intracellular Signaling Peptides and Proteins*, Triazoles*, Animals, Blood-Brain Barrier, Cell Line, Tumor, Cell Proliferation, Humans, Mice, Neoplastic Stem Cells, Xenograft Model Antitumor Assays (* major topic)
Topic: Epigenetics and DNA Methylation (Molecular Biology, Biochemistry, Genetics and Molecular Biology), according to OpenAlex
Funding: Dr. Ralph and Marian Falk Medical Research Trust (Catalyst Award)
Citations: not cited yet (Europe PMC); 104 references in the paper

Abstract

Glioblastoma (GBM) cancer stem cells (CSCs) contribute to tumor recurrence, treatment resistance, and dismal clinical outcomes. Genetic and pharmacological evidence suggests that the nuclear scaffolding protein WD-repeat containing protein 5 (WDR5) is a therapeutic vulnerability of the CSC population. However, previously reported WDR5 inhibitors display low permeability and are unable to penetrate the blood-brain barrier (BBB), limiting their utility in GBM. Herein, we report the structure-guided development of a series of triazole-based WDR5 WIN-site inhibitors designed to increase passive brain penetration. We identified triazole-based WDR5 inhibitors that are potent, passively permeable, and in some cases more brain penetrant than other scaffolds. We phenotypically assessed our WDR5 inhibitors in a panel of patient-derived CSC models and uncovered unique WDR5-regulated metabolic genes in GBM. We also evaluated their antiproliferative activity against CSCs both in vitro and in vivo. Finally, to identify potential combination opportunities, we screened a 2,100-compound chemical probe library and identified that the ATAD2 inhibitor BAY-850 synergizes with WDR5 inhibitors to enhance CSC killing. Our work diversifies the chemical matter targeting WDR5, clarifies the in vitro consequences of WIN-site inhibition in CSCs, and encourages the future development of next-generation WDR5 inhibitors with the potential to achieve in vivo efficacy in the brain.

Reproduced under the paper's license (CC BY), from the paper cited above.

Code

The paper links to its data and to no code of its authors: see the Data section.

Tracing map

A tracing map links a paper to the code its authors published: this paper has none, so it has no map.

Data

Datasets cited

Data availability

RNA-seq data associated with this manuscript have been deposited to GEO (GSE304999 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE304999)). Crystallographic maps and coordinates were deposited to the Protein Data Bank (PDB: 9NCW, 9NCT, 9NCV). All other data are provided in the main text and/or the associated Supporting Data Values file.

Reproduced under the paper's license (CC BY), from the paper cited above.

Versions

The history of this record: each version stored by the harvester or made by a correction of its authors or of the maintainers of its code, and what changed in its facts. The texts of the paper (its abstract, its availability statements) are not part of it; versions that changed only those are not listed.

Version 2, 28 September 2026

  • Authors: added Jonathan Macdonald (0000-0002-6360-2768); Feixiong Cheng (0000-0002-1736-2847); Shaun R Stauffer (0000-0002-6332-1827); removed Jonathan Macdonald; Feixiong Cheng; Shaun R Stauffer

Version 1, 28 September 2026: the first record

Recorded: type, language, journal, volume, issue, pages, dates, 24 authors, 6 keywords, 13 MeSH terms, 1 funder, 103 references.

Cite

This paper

Coker, J. A., Martinez, S. R., Han, S. H., Sloan, A. R., Gupta, A. K., Bukenya, G., Polzer, P., Ramos, J. H., Rico, E. G., Rico, A., Lindsey, A. A., Navadgi, T., Reitz, N., Romigh, T., Macdonald, J., Sonawane, D., Goins, C. M., Hubert, C. G., Wang, N. S., . . . Stauffer, S. R. (2026). Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma. JCI insight, 11(12), e198298. https://doi.org/10.1172/jci.insight.198298

BibTeX

@article{coker2026development,
author = {Coker, Jesse A and Martinez, Steven R and Han, Sang Hoon and Sloan, Anthony R and Gupta, Amit Kumar and Bukenya, George and Polzer, Paul and Ramos, James H and Rico, Emma G and Rico, Annabella and Lindsey, A Abigail and Navadgi, Tanvi and Reitz, Natalie and Romigh, Todd and Macdonald, Jonathan and Sonawane, Dhiraj and Goins, Christopher M and Hubert, Christopher G and Wang, Nancy S and Cheng, Feixiong and Alvarado, Joseph and Sprowls, Samuel A and Lathia, Justin D and Stauffer, Shaun R},
title = {{Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma}},
journal = {JCI insight},
year = {2026},
month = may,
volume = {11},
number = {12},
pages = {e198298},
publisher = {American Society for Clinical Investigation},
issn = {2379-3708},
doi = {10.1172/jci.insight.198298},
url = {https://doi.org/10.1172/jci.insight.198298},
pmid = {42084925},
pmcid = {PMC13313556}
}

RIS

TY - JOUR
AU - Coker, Jesse A
AU - Martinez, Steven R
AU - Han, Sang Hoon
AU - Sloan, Anthony R
AU - Gupta, Amit Kumar
AU - Bukenya, George
AU - Polzer, Paul
AU - Ramos, James H
AU - Rico, Emma G
AU - Rico, Annabella
AU - Lindsey, A Abigail
AU - Navadgi, Tanvi
AU - Reitz, Natalie
AU - Romigh, Todd
AU - Macdonald, Jonathan
AU - Sonawane, Dhiraj
AU - Goins, Christopher M
AU - Hubert, Christopher G
AU - Wang, Nancy S
AU - Cheng, Feixiong
AU - Alvarado, Joseph
AU - Sprowls, Samuel A
AU - Lathia, Justin D
AU - Stauffer, Shaun R
TI - Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma
T2 - JCI insight
J2 - JCI Insight
PY - 2026
DA - 2026/05/05
VL - 11
IS - 12
SP - e198298
SN - 2379-3708
PB - American Society for Clinical Investigation
DO - 10.1172/jci.insight.198298
UR - https://doi.org/10.1172/jci.insight.198298
LA - en
ER -

CSL-JSON

{
"id": "10.1172/jci.insight.198298",
"type": "article-journal",
"title": "Development and characterization of triazole-based WDR5 inhibitors for the treatment of glioblastoma",
"container-title": "JCI insight",
"author": [
{
"family": "Coker",
"given": "Jesse A"
},
{
"family": "Martinez",
"given": "Steven R"
},
{
"family": "Han",
"given": "Sang Hoon"
},
{
"family": "Sloan",
"given": "Anthony R"
},
{
"family": "Gupta",
"given": "Amit Kumar"
},
{
"family": "Bukenya",
"given": "George"
},
{
"family": "Polzer",
"given": "Paul"
},
{
"family": "Ramos",
"given": "James H"
},
{
"family": "Rico",
"given": "Emma G"
},
{
"family": "Rico",
"given": "Annabella"
},
{
"family": "Lindsey",
"given": "A Abigail"
},
{
"family": "Navadgi",
"given": "Tanvi"
},
{
"family": "Reitz",
"given": "Natalie"
},
{
"family": "Romigh",
"given": "Todd"
},
{
"family": "Macdonald",
"given": "Jonathan"
},
{
"family": "Sonawane",
"given": "Dhiraj"
},
{
"family": "Goins",
"given": "Christopher M"
},
{
"family": "Hubert",
"given": "Christopher G"
},
{
"family": "Wang",
"given": "Nancy S"
},
{
"family": "Cheng",
"given": "Feixiong"
},
{
"family": "Alvarado",
"given": "Joseph"
},
{
"family": "Sprowls",
"given": "Samuel A"
},
{
"family": "Lathia",
"given": "Justin D"
},
{
"family": "Stauffer",
"given": "Shaun R"
}
],
"container-title-short": "JCI Insight",
"volume": "11",
"issue": "12",
"page": "e198298",
"DOI": "10.1172/jci.insight.198298",
"PMID": "42084925",
"PMCID": "PMC13313556",
"ISSN": "2379-3708",
"publisher": "American Society for Clinical Investigation",
"URL": "https://doi.org/10.1172/jci.insight.198298",
"language": "en",
"issued": {
"date-parts": [
[
2026,
5,
5
]
]
}
}

Similar papers

The papers with a page that share the most with this one: the tools found in their code, their categories, datasets, cited references and authors, the rarest counting most.

[1] doi:10.3390/cancers15184619
Repurposing Clemastine to Target Glioblastoma Cell Stemness.
Journal: Cancers
In common: other condition, 7 references
[2] doi:10.1038/s43018-023-00556-5
GAP43-dependent mitochondria transfer from astrocytes enhances glioblastoma tumorigenicity.
Journal: Nature cancer
In common: other condition, 3 references, author Feixiong Cheng
[3] doi:10.1038/s41586-024-08371-3
Bidirectional histone monoaminylation dynamics regulate neural rhythmicity.
Journal: Nature
In common: mouse, 5 references
[4] doi:10.1038/s41467-025-60228-z
Elevated nonhomologous end-joining by AATF enables efficient DNA damage repair and therapeutic resistance in glioblastoma.
Journal: Nature communications
In common: other condition, mouse, 4 references
[5] doi:10.1093/neuonc/noab269
Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
Journal: Neuro-oncology
In common: other condition, 4 references
[6] doi:10.1016/j.stemcr.2026.103013
Targeting mitotic kinesin KIF20A: A differentiation-based therapeutic strategy for glioblastoma stem/progenitor cells.
Journal: Stem cell reports
In common: other condition, mouse, 4 references
[7] doi:10.1021/acs.jmedchem.4c02694
Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome.
Journal: Journal of medicinal chemistry
In common: other condition, mouse, 4 references
[8] doi:10.1016/j.celrep.2025.115746 [code]
Division of labor among H3K4 methyltransferases defines distinct facets of homeostatic plasticity.
Journal: Cell reports
In common: other condition, mouse, 4 references
[9] doi:10.3233/jad-231391
Sildenafil as a Candidate Drug for Alzheimer's Disease: Real-World Patient Data Observation and Mechanistic Observations from Patient-Induced Pluripotent Stem Cell-Derived Neurons.
Journal: Journal of Alzheimer's disease : JAD
In common: 6 references
[10] doi:10.1016/j.celrep.2026.117408
NAT10-dependent N<sup>4</sup>-acetylcytidine reprograms R-loops and promotes cancer stem cell growth.
Journal: Cell reports
In common: other condition, mouse, 3 references

Contribute

The authors of this paper can claim it, correct its record and validate its tracing map, and the maintainers of its code (its owner, or a public member of its organization) correct what it says of their repository; anyone signed in can ask for its removal. Every request goes to OSCR's own machine, which answers it; your account page follows them.

Sign in with ORCID to claim this paper as one of its authors, correct its record or validate its tracing map: when the paper's metadata lists your ORCID iD, you are recognized at once. Maintainers of its code: sign in with GitHub, then claim the repository on your account page.

Request its removal

To ask OSCR to remove this record, the copies of its authors' scripts or its tracing map, use the removal request page: signed in, you say who you are, what to remove and why, then review and confirm the request. Published rules decide every request (how).

Discussion, reproductions, activity

Discussion: code errors and mismatches between the code and the paper about this paper and its code, from readers and its authors, beside the paper and its tracing map.

Reproductions: reports from readers who ran the authors' code and did not get the paper's result, what they ran, with which environment, commit and data.

Activity: what happens around this paper: new versions of its record, its map's validation, discussions and reproductions. It opens with sign-in.